バイオシミラー及びバイオ後続品の世界市場

◆英語タイトル:Global Biosimilars and Follow-On Biologics Market 2017-2027
◆商品コード:VGAIN705044
◆発行会社(調査会社):visiongain
◆発行日:2017年5月
◆ページ数:318
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥387,345見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、バイオシミラー及びバイオ後続品の世界市場について調査・分析し、バイオシミラー及びバイオ後続品の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・バイオシミラー及びバイオ後続品の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・バイオシミラー及びバイオ後続品の世界市場:セグメント別市場分析
・バイオシミラー及びバイオ後続品の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast period. The market is estimated at $5.31bn in 2016 and $41.07bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 318-page report you will receive 128 tables and 68 figures – all unavailable elsewhere.

The 318-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Biosimilars and Follow-on Biologics Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2027 for 8 individual therapeutic submarkets:
- Monoclonal antibodies (mAbs)
- Fusion proteins
- Insulin
- Erythropoietin (EPO)
- Granulocyte colony-stimulating factor (G-CSF)
- Interferons
- Growth hormones
- Fertility hormones

• This report also shows revenue to 2027 for 12 individual submarkets within the above segments:
- Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
- Human insulin, insulin analogues, insulin glargine and insulin lispro
- Interferon alfa and interferon beta
- Etanercept

• Our analyses show individual revenue forecasts to 2027 for 12 national markets:
- US
- Japan
- Germany, France, UK, Italy and Spain
- China, India, South Korea, Russia and Brazil

• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market from 2016, including these influences:
- Strategies for developing biosimilars – needs, demand, challenges and opportunities
- Guidelines from regulators (FDA, EMA and others)
- Patent challenges and data exclusivity for biopharmaceuticals
- Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
- Developments in technology and operations for biosimilar drug production.

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars and follow-on biologics market. You find data, trends and predictions.

Buy our report today Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones.

【レポートの目次】

1. Report Overview
1.1 Biosimilars Overview
1.2 Biosimilars Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain

2. An Introduction to Biosimilars and Biosimilar Drug Development
2.1 What are Biologics?
2.1.1 Biologics can be Very Effective but also Very Expensive
2.1.2 Brief History of Biological Drug Development
2.1.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
2.2 What are Biosimilars?
2.3 Brief History of Biosimilars
2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars?
2.4.1 FDA Guidelines on Prescription of Interchangeables vs Biosimilars
2.4.2 Where does the EMA Stand with Regard to Interchangeables?
2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?
2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?
2.5 Main Segments of the Overall Biosimilars Market

3. The Global Biosimilars Market 2016-2027
3.1 The Global Biosimilars Market
3.2 Biosimilars as a Share of the Biologics Market, 2016
3.2.1 Seven of the Top Ten Best-Selling Drugs are Biologics
3.2.2 Outlook for the Overall Biologics Market
3.3 Global Biosimilars Market Forecast, 2016-2027
3.4 What will Drive Growth in the Biosimilars Market?
3.4.1 Biosimilars Can Bring about Savings of Billions – $44bn for the US by 2024 and $33bn for Europe by 2020
3.4.2 Over $67bn Worth of Biologic Patents due to Expire by 2020
3.4.3 US Approves First Biosimilar – Zarxio. Will this Open the Floodgates? Interchangeability Can also Drive Growth
3.4.4 Other Developed and Emerging Markets Will also Provide Opportunities for Growth
3.4.5 Competitive Landscape Emerging for Biosimilars
3.5 What Factors can Restrain Sales Growth in the Biosimilars Market?
3.5.1 Complexity of Biologics Means that Biosimilar Development Faces Many Challenges
3.5.2 Opposition from Originator Companies and Patent Issues
3.5.3 Fragmentation in the Market as Many Companies Chase the Same Targets
3.5.4 The Threat of Biobetters and Next-Generation Biologics
3.6 Summary of the Drivers and Restraints for the Global Biosimilars Market
3.7 Global Biosimilars Market Forecast by Submarket, 2016-2027
3.7.1 Leading Segments in the Biosimilars Market
3.7.2 How Will the Composition of the Market Change Over the Next Ten Years?

4. Outlook for Biosimilars in Leading Developed Markets, 2016-2027
4.1 The Leading National Biosimilar Submarkets
4.2 National Submarket Forecasts 2016-2027
4.3 How will the Regional Composition of the Global Market Change from 2016-2027?
4.4 US Biosimilars Market Outlook 2016-2027
4.4.1 Status of the US Market in 2014-2016
4.4.2 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
4.4.2.1 The History of the US’ Biosimilar Guidelines
4.4.3 FDA Finally Releases Guidance on Biosimilar Naming in August 2015
4.4.4 Individual States Can Pass their Own Biosimilar Substitution Laws
4.4.5 US Biosimilars Market Forecast 2016-2027
4.5 The EU Biosimilar Market: History and Current Status
4.5.1 History of EMA Guidelines and Updates
4.5.2 Biosimilar Uptake in the Europe Varies between Nations
4.5.3 European Biosimilars Market Forecast, 2016-2027
4.5.4 Inflectra and Remsima in Europe – Demonstrates a Path for Other Biosimilar mAbs
4.5.5 German Biosimilar Market Outlook, 2016
4.5.5.1 German Biosimilar Market Forecast, 2016-2027
4.5.6 French Biosimilars Market Outlook, 2016
4.5.6.1 Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year
4.5.6.2 French Biosimilar Market Forecast, 2016-2027
4.5.7 UK Biosimilar Market Outlook, 2016
4.5.7.1 UK Biosimilar Market Forecast, 2016-2027
4.5.8 Italian Biosimilars Market Outlook, 2016
4.5.8.1 Italian Biosimilars Market Forecast, 2016-2027
4.5.9 Spanish Biosimilars Market Outlook, 2016
4.5.9.1 Spanish Biosimilar Market Forecast, 2016-2027
4.5.10 Biosimilar Regulation in Japan and Currently Approved Biosimilars
4.5.10.1 Differences between the European and Japanese Guidelines
4.5.10.2 Currently Approved Biosimilars in Japan
4.5.10.3 Japanese Biosimilar Market Forecast, 2016-2027

5. Outlook for Biosimilars in Emerging Markets, 2016-2027
5.1 China and India Lead Biosimilar Revenues
5.2 Leading Emerging Biosimilar Markets Forecast, 2016-2027
5.3 Chinese Biosimilars Market Outlook, 2016
5.3.1 China Publishes Final Guidelines for Biosimilars
5.3.2 Biosimilars Account for less than Half of Biotech Revenues in China
5.3.3 Chinese Biosimilars Market Forecast, 2016-2027
5.4 Indian Biosimilars Market Outlook, 2016
5.4.1 CDSCO Guidelines Released in 2012
5.4.2 Indian Biosimilars Market Forecast, 2016-2027
5.5 South Korea’s Established Biosimilar Guidelines
5.5.1 Currently Approved Biosimilars in South Korea, 2016
5.5.2 South Korean Biosimilars Market Forecast, 2016-2027
5.6 Russian Biosimilars Market Outlook and Forecast, 2016-2027
5.7 Brazilian Biosimilar Regulation
5.7.1 Government Eager to Promote Biosimilar Development, and Two Major Conglomerates, Bionovis and Orygen, are Racing to Produce Biosimilars
5.7.2 Brazilian Biosimilars Market Forecast, 2016-2027

6. Biosimilar Monoclonal Antibodies: Submarket Forecast and Pipeline, 2016-2027
6.1 MAbs as Part of the Overall Biologics Market in 2016
6.2 Monoclonal Antibodies (mAbs): Largest Biologic Submarket, with Individual Drugs Accumulating Multi-Billion Dollar Revenues
6.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2016-2027
6.4 Drivers for the Biosimilar Monoclonal Antibodies Market
6.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
6.4.2 Rising Incidence of Cancer will Drive Demand
6.4.3 The Need for Lower Cost Therapies
6.4.4 Partnering to Launch Biosimilar mAbs
6.5 Restraints for the Monoclonal Antibodies Market
6.5.1 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
6.5.1.1 Hope for Biosimilars when Competing Against Next-Generation Therapies
6.5.2 Challenges in Antibody Development and Manufacturing
6.5.3 Patent Issues, Market Fragmentation and Perception of Biosimilars
6.6 Leading Targets for Biosimilar Development, 2016-2027
6.7 Biosimilar Rituximab
6.7.1 Rituxan: The First Anti-Cancer mAb
6.7.2 Approved Biosimilars and Rituxan Patent Expiry
6.7.2.1 Reditux (Dr. Reddy’s Laboratories): First Biosimilar Rituximab
6.7.2.2 MabTas (Intas Pharmaceutical): Another Indian Biosimilar
6.7.2.3 AcellBia (Biocad): The Leading Biosimilar Rituximab
6.7.2.4 Kikuzubam (PROBIOMED) – Faced Challenges
6.7.3 Biosimilar Rituximab Pipeline, 2016-2027
6.7.3.1 Terminated Developments
6.7.3.2 GP2013 (Sandoz): One of the Biggest Names in the Biosimilar Industry Throws its Hat into the Ring with Advanced Stage Candidate
6.7.3.3 BI 695500 (Boehringer Ingelheim)
6.7.3.4 MabionCD20 (Mabion): Focusing on Markets with High Demand
6.7.3.5 CT-P10 (Celltrion)
6.7.3.6 PF-05280586 (Pfizer)
6.7.4 Biosimilar Rituximab: Revenue Forecast 2016-2027
6.8 Biosimilar Infliximab
6.8.1 Remicade: Second Only to Humira
6.8.2 Approved Biosimilars and Remicade Patent Expiry: Uncertainty in the US after FDA Rejection
6.8.2.1 Inflectra and Remsima (Hospira and Celltrion)
6.8.2.2 Celltrion Speeds Ahead with US FDA Filing, and Inflectra Approved in Australia and Canada
6.8.2.3 Infliximab and BOW015 (Epirus Biopharmaceuticals and Ranbaxy Laboratories)
6.8.3 Biosimilar Infliximab Pipeline, 2015-2027
6.8.3.1 SB2 (Samsung Bioepis): Has been Filed for EU Approval and Shows Positive Phase 3 Results
6.8.3.2 NI-071 (Nichi-Iko): Advanced Stages
6.8.3.3 ABP 710 (Amgen) and BX2922 (BioXpress Therapeutics)
6.8.4 Biosimilar Infliximab: Revenue Forecast 2016-2027
6.9 Biosimilar Trastuzumab
6.9.1 Herceptin: Another Jewel in Roche’s Cancer mAb Portfolio
6.9.2 Approved Biosimilars and Herceptin Patent Expiry
6.9.2.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
6.9.2.2 Herzuma (Celltrion)
6.9.3 Biosimilar Trastuzumab Pipeline, 2015-2027
6.9.3.1 BCD-022 (Biocad): Leading Biosimilar Rituximab Developer Tries its Hand at Trastuzumab
6.9.3.2 ABP 980 (Amgen and Allergan): Phase 3
6.9.3.3 PF-05280014 (Pfizer): Phase 3
6.9.3.4 SB3 (Samsung Bioepis) and BX2318 (BioXpress Therapeutics)
6.9.4 Biosimilar Trastuzumab: Revenue Forecast 2016-2027
6.10 Biosimilar Adalimumab
6.10.1 Humira – The World’s Best-Selling Prescription Drug
6.10.2 Approved Biosimilars and Humira Patent Expiry
6.10.2.1 Exemptia (Zydus Cadila): The First Biosimilar Adalimumab
6.10.3 Biosimilar Adalimumab Pipeline, 2015-2027
6.10.3.1 ABP 501 (Amgen and Allergan): Positive Phase 3 Results Released
6.10.3.2 GP2017 (Sandoz): Phase 3
6.10.3.3 BI 695501 (Boehringer Ingelheim)
6.10.3.4 SB5 (Samsung Bioepis): Phase 3 Results
6.10.4 Biosimilar Adalimumab: Revenue Forecast 2016-2027
6.11 Biosimilar Bevacizumab
6.11.1 Avastin: High Revenues and Late Patent Expiry
6.11.2 Biosimilar Bevacizumab Pipeline, 2016-2027
6.11.2.1 BCD-021 (Biocad)
6.11.2.2 ABP 215 (Amgen and Allergan): Positive Phase 3 Results
6.11.2.3 BI 695502 (Boehringer Ingelheim): Phase 3
6.11.2.4 PF-06439535 (Pfizer): Phase 3
6.11.3 Biosimilar Bevacizumab: Revenue Forecast, 2016-2027

7. Biosimilar Fusion Proteins: Submarket Forecast and Pipeline, 2016-2027
7.1 Scientific Background
7.2 Differentiating Fusion Proteins
7.3 Fusion Proteins as Part of the Overall Biologics Market
7.4 Biosimilar Fusion Proteins Market Forecast, 2016-2027
7.5 Biosimilar Etanercept, 2016-2027
7.5.1 Enbrel is the Leading Fusion Protein
7.5.2 Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
7.5.3 Multiple Biosimilars Available in Emerging Markets
7.5.3.1 Brenzys / SB4 (Merck and Samsung Bioepis): First Product Approval to Result from Biosimilar Collaboration
7.5.3.2 Yi Sai Pu (Shanghai CP Guojian Pharmaceutical) and Qiangke (Shanghai Celgen Biopharmaceutical)
7.5.3.3 Etacept (Cipla) and Intacept (Intas Pharmaceuticals)
7.5.3.4 Davictrel / HD-203 (Hanwha Chemical and Merck KGaA)
7.5.4 Biosimilar Etanercept Pipeline
7.5.5 GP2015 (Sandoz)
7.5.5.1 Sandoz Goes in Early: FDA Accepts Application for GP2015, Despite the Fact that Enbrel Patents are not due to Expire any time Soon
7.5.6 SB4 (Samsung Bioepis): EMA Accepts Application
7.5.6.1 Samsung Bioepis Releases Positive Phase 3 Data for SB4
7.5.7 CHS-0214 (Coherus Biosciences and Baxter)
7.5.8 TuNEX / ENIA11 (Mycenax Biotech / TSH Biopharm Corp): Phase 3 in Taiwan
7.5.9 LBEC0101 (LG Life Sciences): Phase 3
7.5.10 Biosimilar Etanercept: Revenue Forecast 2016-2027
7.6 Eylea and Biosimilar Aflibercept
7.7 Orencia and Biosimilar Abatacept

8. Biosimilar Insulin Submarket Outlook, 2016-2027
8.1 Insulin as Part of the Biological Drug Sector
8.2 30 Million People Expected to be Diagnosed with Diabetes by 2030
8.3 Approved Insulin Biosimilars
8.4 Abasaglar / Basaglar / Insulin Glargine BS – The First Insulin Biosimilars to be Approved in Developed Markets
8.5 EMA Releases Finalised Insulin Biosimilars Guideline
8.6 Basaglar Delayed in the US until End of 2016
8.7 Biosimilar Insulin Market and Submarkets Forecast, 2016-2027
8.8 Biosimilar Human Insulin Submarket, 2016-2027
8.8.1 A Submarket Mostly Restricted to Emerging Markets?
8.8.2 Biosimilar Human Insulin in China
8.8.3 Biosimilar Human Insulin in India
8.8.3.1 Wockhardt and Biocon – Given up on their Desire to Target the US and Europe?
8.8.4 Biosimilar Human Insulin in Russia
8.8.5 Biosimilar Human Insulin Submarket Forecast, 2016-2027
8.9 Biosimilar Insulin Analogues Submarket, 2016-2027
8.9.1 Available Biologic Insulin Analogues – Sanofi’s Lantus Tops Revenues
8.9.2 Insulin Glargine in the Main Biosimilar Target
8.9.2.1 Limited Development for the Other Targets
8.9.3 Insulin Market Leaders are Developing Ultra-Rapid Acting Insulin Analogues
8.9.3.1 Ultra-Long Acting Insulin also in Development
8.9.4 Mylan Partners with Biocon for Insulin Analogues
8.9.5 Biosimilar Insulin Analogue Revenue Forecast, 2016-2027
8.10 Biosimilar Insulin Glargine
8.10.1 Biosimilars in India and China
8.10.2 Biosimilar Insulin Glargine Pipeline
8.10.2.1 MK-1293 (Merck / Samsung Bioepis)
8.10.2.2 Mylan’s Insulin Glargine (Mylan and Biocon)
8.10.3 Biosimilar Insulin Glargine: Revenue Forecast, 2016-2027
8.11 Biosimilar Insulin Lispro
8.11.1 One Biosimilar is Currently Available – Prandlin
8.11.2 Much Smaller Pipeline than for Insulin Glargine
8.11.3 Biosimilar Insulin Lispro: Revenue Forecast, 2016-2027

9. Biosimilar Erythropoietins Submarket Outlook, 2016-2027
9.1 Three Products Lead the Biologic EPO Therapy Market
9.2 Safety Concerns for Erythropoietin-Stimulating Agents
9.3 The Challenge from Oral Therapies is Coming
9.4 Treating Anaemia in Patients with CKD – the Leading Use of EPO Therapies
9.5 Biosimilar Epoetin Approvals in Europe
9.6 Epoetin Alfa Pipeline for the European Market
9.7 Trends in Uptake for Biosimilar Epoetins in Europe
9.8 Epoetin Alfa Pipeline for the US – Companies Preparing for Launch
9.8.1 Pfizer’s Retacrit Delayed after Response Letter from FDA
9.8.2 Binocrit / HX575 has Completed Trials
9.9 Biosimilar Epoetin in Japan
9.10 Biosimilar Epoetin in South Korea
9.11 Biosimilar Epoetin in India and China
9.12 Second-Generation EPO Biosimilars
9.13 No Mircera Biosimilars in Clinical Development
9.14 Biosimilar EPO Market Forecast, 2016-2027

10. Biosimilar G-CSF Submarket Outlook, 2016-2027
10.1 Amgen Leads the Branded Biologic G-CSF Market
10.2 Teva Launches Long-Acting Pegfilgrastim
10.3 Selected Filgrastim Biosimilars Approved Worldwide
10.3.1 The European G-CSF Biosimilars Market
10.3.1.1 Trends in Biosimilar Uptake Across Europe
10.3.2 Tevagrastim (Teva): The First Biosimilar in Europe, Launched as Granix in the US
10.3.3 Nivestim (Hospira – Pfizer)
10.3.4 Zarzio (Sandoz): The Most Prescribed Biosimilar Therapy in Europe
10.3.5 Zarxio Becomes the First Biosimilar to be Approved in the US, Launched in September
10.3.6 Apotex: FDA has Accepted Applications for both its Biosimilar Filgrastim, and its Biosimilar Pegfilgrastim
10.3.7 Multiple Launches in Japan in Recent Years
10.3.8 Biosimilar Filgrastim and Pegfilgrastim in India
10.3.9 Biosimilars in Russia, China and Other Emerging Markets
10.4 Biosimilar G-CSF Market Forecast, 2016-2027

11. Biosimilar Interferons Submarket Outlook, 2016-2027
11.1 Interferons: Key Antiviral and MS Therapies Since the 1990s
11.2 Leading Interferon Brands
11.3 Competition for the Multiple Sclerosis Market – Challenges for Interferon Beta Therapies
11.4 All-Oral Regimens will Challenge Interferon Alfa Therapy
11.4.1 However Oral Therapies will be Expensive
11.5 There are no Approved Biosimilars in Developed Markets
11.6 Biosimilar Interferon Market Forecast, 2016-2027
11.7 Biosimilar Interferon Alfa
11.7.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, Leading to Fragmented Markets
11.7.2 Biosimilar Peginterferon Alfa
11.7.3 Hepatitis Treatment Rates are Low
11.7.4 Biosimilar Interferon Alfa Submarket Forecast, 2016-2027
11.8 Biosimilar Interferon Beta
11.8.1 Biosimilars are Well-Established in Emerging Markets
11.8.2 Biosimilar Interferon Beta Pipeline
11.8.3 EMA Guidance
11.8.4 Long-Acting Interferon Beta
11.8.5 Biosimilar Interferon Beta Submarket Forecast, 2016-2027

12. Biosimilar Recombinant Hormones Submarket Outlook, 2016-2027
12.1 Human Growth Hormone: First Extracted in 1958
12.2 Biologic Growth Hormone Market in 2014 – Novo Nordisk and Pfizer Dominate
12.2.1 Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
12.3 Biosimilar Growth Hormones
12.3.1 Omnitrope – Well Established in Developed Markets
12.4 Multiple Biosimilars Available Worldwide
12.4.1 Biosimilars Growth Hormones Outside of Asia
12.4.2 Biosimilar Growth Hormones in Asia
12.4.3 Biosimilar Uptake Varies by Region
12.5 Biosimilar Growth Hormones Market Forecast, 2016-2027
12.6 Fertility Hormones
12.6.1 Two Products Lead the Branded Fertility Hormone Market
12.6.2 Long-Acting Follicle Stimulating Hormone (FSH)
12.6.3 Branded Fertility Hormones Market Outlook
12.6.4 Available Biosimilar Fertility Hormones
12.6.5 Biosimilars Approved in Europe
12.6.5.1 Ovaleap (Teva)
12.6.5.2 Befomla (Finox Biotech) Approved in Europe, Undergoing Phase 3 for US
12.6.6 Rising Infertility to Drive Demand to 2027
12.6.7 Biosimilar Fertility Hormones Market Forecast, 2016-2027

13. Biosimilars: Qualitative Analysis and Industry Trends
13.1 SWOT Analysis of the Biosimilars Market
13.2 Biosimilars Market: Strengths
13.2.1 Biosimilars Can Offer Huge Cost Savings
13.2.2 The US has Finally Joined the Global Biosimilars Market
13.2.3 Biosimilars are Already Well-Established in Many National Markets
13.2.4 Outsourcing Offers the Chance for Further Cost Savings
13.3 Biosimilars Market: Weaknesses
13.3.1 Biosimilars are High Cost to Develop and Manufacture
13.3.2 Complexity Means that Development Timelines are Long
13.3.3 Uptake for Biosimilars Varies and is Low in Some Regions
13.4 Biosimilars Market: Opportunities
13.4.1 Blockbuster Biologics Face Patent Expiry
13.4.2 Rising Disease Prevalence
13.4.3 Licensing Agreements for Biosimilars
13.5 Threats
13.5.1 Biobetters and Next-Generation Biologics
13.5.2 Patent Issues and Product Life Cycle Management from Originator Companies
13.5.3 Fragmentation in the Market
13.5.4 Long Market and Data Exclusivity Periods
13.5.5 Biosimilars Require Marketing and Education
13.6 Biosimilar Product Pipeline

14. Conclusions from Visiongain’s Research and Analysis
14.1 Rapid Growth Expected for this High-Potential Market
14.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
14.3 A Range of Factors Will Stimulate Demand
14.4 Challenges Remain in Developing and Successfully Launching Biosimilars

Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 Sample Table 1
Table 1.2 Sample Table 2
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 3.1 Top Ten Best-Selling Drugs of 2016 (Wihtin the Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)
Table 3.2 Global Biosimilars Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.3 Global Biosimilars Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.4 Patent Status for Leading Biologics within the Overall Biologics Market, 2016
Table 3.5 Biosimilars Market Forecast by Submarket (Insulin, EPO, G-CSF, Growth Hormones, mAbs): Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2014-2020
Table 3.6 Biosimilars Market Forecast by Submarket (Interferons, Fusion Proteins, Fertility Hormones, Other Biosimilars): Revenue ($bn), AGR (%),CAGR (%), Market Shares (%), 2014-2020
Table 3.7 Biosimilars Market Forecast by Submarket (Insulin, EPO, G-CSF, Growth Hormones, mAbs): Revenue ($bn), AGR (%),CAGR (%), Market Shares(%), 2021-2027
Table 3.8 Biosimilars Market Forecast by Submarket (Interferons, Fusion Proteins, Fertility Hormones, Other Biosimilars): Revenue ($bn), AGR (%),CAGR (%), Market Shares (%), 2021-2027
Table 4.1 Global Biosimilars Market by Region: Revenues ($bn), Market Share (%), 2016
Table 4.2 Global Biosimilars Market Forecast Segmented by Nation (China, EU, India, US, South Korea, Japan): Revenue ($bn), AGR (%),CAGR (%),Market Share(%), 2014-2020
Table 4.3 Global Biosimilars Market Forecast Segmented by Nation (Russia, Brazil, Other): Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.4 Global Biosimilars Market Forecast Segmented by Nation (China, EU, India, US, South Korea, Japan): Revenue ($bn), AGR (%),CAGR (%),Market Share (%), 2021-2027
Table 4.5 Global Biosimilars Market Forecast Segmented by Nation (Russia, Brazil, Other): Revenue ($bn), AGR (%), CAGR (%), Market Share(%), 2021-2027
Table 4.6 U.S. Biosimilar Approvals To-Date, 2017
Table 4.7 US Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.8 US Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.9 European Biosimilar Approvals: Monoclonal Antibodies and Insulin
Table 4.10 European Biosimilar Approvals: G-CSF
Table 4.11 European Biosimilar Approvals: EPO
Table 4.12 European Biosimilar Approvals: Growth Hormones and Fertility Hormones
Table 4.13 European Biosimilars Market Segmented by Leading Nations: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.14 European Biosimilars Market Segmented by Leading Nations: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.15 German Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.16 German Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.17 French Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.18 French Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.19 UK Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.20 UK Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.21 Italian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.22 Italian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.23 Spanish Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.24 Spanish Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 4.25 Japanese Biosimilar Approvals To-Date, 2016
Table 4.26 Japanese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 4.27 Japanese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 5.1 Leading Emerging Biosimilar Markets: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 5.2 Leading Emerging Biosimilar Markets: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 5.3 Chinese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 5.4 Chinese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 5.5 Indian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 5.6 Indian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 5.7 Currently Approved Biosimilars in South Korea, 2016
Table 5.8 South Korean Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 5.9 South Korean Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 5.10 Russian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 5.11 Russian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 5.12 Brazilian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 5.13 Brazilian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.1 The Best-Selling mAbs of 2016: Revenue ($bn), 2016
Table 6.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.3 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.4 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.5 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.6 Patent Status of Five Leading mAbs, 2016
Table 6.7 Types of Next-Generation Antibody Therapy, 2016
Table 6.8 Past and Present GP2013 (Sandoz) Clinical Trials, 2016
Table 6.9 Ongoing BI 695500 (Boehringer Ingelheim) Clinical Trials, 2016
Table 6.10 Ongoing CT-P10 (Celltrion) Clinical Trials, 2016
Table 6.11 Past and Present PF-05280586 (Pfizer) Clinical Trials, 2016
Table 6.12 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.13 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.14 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.15 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.16 Ongoing PF-05280014 (Pfizer) Clinical Trials, 2016
Table 6.17 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.18 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.19 Recent ABP 501 (Amgen and Allergan) Clinical Trials, 2016
Table 6.20 Ongoing BI 695501 (Boehringer Ingelheim) Clinical Trials, 2016
Table 6.21 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.22 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.23 Recent BCD-021 (Biocad) Clinical Trials, 2016
Table 6.24 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 6.25 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 7.1 Biosimilar Fusion Proteins Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 7.2 Biosimilar Fusion Proteins Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 7.3 Amgen’s US Patents and Expiry Dates for Enbrel
Table 7.4 Ongoing CHS-0214 (Coherus Biosciences and Baxter) Clinical Trials, 2016
Table 7.5 Biosimilar Etanercept Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 7.6 Biosimilar Etanercept Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 8.1 Diabetes Prevalence in Leading National Markets, 2012
Table 8.2 Selected Insulin Biosimilars which have been Approved and Launched
Table 8.3 Biosimilar Insulin Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 8.4 Biosimilar Insulin Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 8.5 Biosimilar Insulin Submarket Forecasts: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 8.6 Biosimilar Insulin Submarket Forecasts: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 8.7 Biosimilar Human Insulin Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 8.8 Biosimilar Human Insulin Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 8.9 Approved Insulin Analogues Marketed Worldwide, 2016
Table 8.10 Biosimilar Insulin Analogues Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 8.11 Biosimilar Insulin Analogues Submarket Forecast: Revenue ($bn), AGR (%),CAGR (%), 2021-2027
Table 8.12 MK-1293 (Merck / Samsung Bioepis) Recent Clinical Trials, 2016
Table 8.13 Insulin Glargine Biosimilar (Mylan and Biocon) Ongoing Clinical Trials, 2016
Table 8.14 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 8.15 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($bn), AGR (%),CAGR (%), 2021-2027
Table 8.16 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 8.17 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($bn), AGR (%),CAGR (%), 2021-2027
Table 9.1 Ongoing ASP1517 (Astellas Pharma) Clinical Trials, 2016
Table 9.2 Binocrit / HX575 (Novartis) Clinical Trials, 2016
Table 9.3 Selected EPO Biosimilars Approved in India
Table 9.4 Biosimilar EPO Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 9.5 Biosimilar EPO Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 10.1 Selected Filgrastim Biosimilars Approved Worldwide
Table 10.2 Biosimilar G-CSF Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 10.3 Biosimilar G-CSF Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 11.1 Types of Interferon Used Therapeutically, 2016
Table 11.2 Approved Branded Interferon Therapies, 2016
Table 11.3 Biosimilar Interferons Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 11.4 Biosimilar Interferons Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 11.5 Selected Interferon Alfa Biosimilars Approved Worldwide, 2016
Table 11.6 Chronic Hepatitis B and C: Global Prevalence by Region, 2014
Table 11.7 Biosimilar Interferon Alfa Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 11.8 Biosimilar Interferon Alfa Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 11.9 Selected Interferon Beta Biosimilars Approved Worldwide
Table 11.10 Biosimilar Interferon Beta Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 11.11 Biosimilar Interferon Beta Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 12.1 Biosimilar Growth Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 12.2 Biosimilar Growth Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 12.3 Recent Bemfola / Afolia (Finox Biotech) Clinical Trials, 2016
Table 12.4 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 12.5 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 13.1 Expected Biologic Patent Expiries, 2016-2029
Table 13.2 Typical Models of Collaboration for Biosimilar Development
Table 13.2 Biosimilars product pipeline
Table 14.1 Biosimilars and Follow-On Biologics Market: Revenue ($bn) and Market Share (%) by Sector, 2016, 2020 and 2027
Table 14.2 Biosimilars and Follow-On Biologics Market: Revenue ($bn) and Market Share (%) by Region, 2016, 2020 and 2027

List of Figures
Figure 1.1 Main Segments and Sub-Segments of the Biosimilars Market, 2016
Figure 3.1 Biosimilars Market as Share of the Overall Biologics Market: Revenue ($bn), Market Share (%), 2016
Figure 3.2 Global Biosimilars Market Forecast: Revenue ($bn), 2014-2027
Figure 3.3 Drivers and Restraints for the Biosimilars Market, 2016
Figure 3.4 Global Biosimilars Market Forecasts by Submarket: Revenue ($bn), 2014-2027
Figure 3.5 Composition of the Biosimilars Market in 2016: Market Shares (%)
Figure 3.6 Composition of the Biosimilars Market in 2020: Market Shares (%)
Figure 3.7 Composition of the Biosimilars Market in 2027: Market Shares (%)
Figure 4.1 Regional Composition of the Biosimilars Market in 2016: Market Shares (%)
Figure 4.2 Global Biosimilars Market Forecast Segmented by Region: Revenue ($bn), 2014-2027
Figure 4.3 Market Shares (%) for the Major Regional Markets, 2014-2027
Figure 4.4 Regional Composition of the Biosimilars Market in 2020: Market Shares (%)
Figure 4.5 Regional Composition of the Biosimilars Market in 2027: Market Shares (%)
Figure 4.6 US Biosimilars Market Forecast: Revenue ($bn), 2014-2027
Figure 4.7 European Biosimilars Market Breakdown: Revenue ($bn), 2014
Figure 4.8 European Biosimilars Market Breakdown: Revenue ($bn), 2020
Figure 4.9 European Biosimilars Market Breakdown: Revenue ($bn), 2027
Figure 4.10 European Biosimilars Market Segmented by Leading Nations: Revenue ($bn), 2014-2027
Figure 4.11 German Biosimilars Market: Revenue ($bn), 2014-2027
Figure 4.12 French Biosimilars Market: Revenue ($bn), 2014-2027
Figure 4.13 UK Biosimilars Market: Revenue ($bn), 2014-2027
Figure 4.14 Italian Biosimilars Market: Revenue ($bn), 2014-2027
Figure 4.15 Spanish Biosimilars Market: Revenue ($bn), 2014-2027
Figure 4.16 Japanese Biosimilars Market: Revenue ($bn), 2014-2027
Figure 5.1 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2014
Figure 5.2 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2020
Figure 5.3 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2027
Figure 5.4 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2014-2027
Figure 5.5 Chinese Biosimilars Market: Revenue ($bn), 2014-2027
Figure 5.6 Indian Biosimilars Market: Revenue ($bn), 2014-2027
Figure 5.7 South Korean Biosimilars Market: Revenue ($bn), 2014-2027
Figure 5.8 Russian Biosimilars Market: Revenue ($bn), 2014-2027
Figure 5.9 Brazilian Biosimilars Market: Revenue ($bn), 2014-2027
Figure 6.1 Monoclonal Antibodies as a Percentage of the Total Biologics Market: Revenue ($bn), Market Share (%), 2016
Figure 6.2 The Best-Selling mAbs of 2016 as a Percentage of the Total Biologics Market: Revenue ($bn), Market Share (%), 2016
Figure 6.3 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), 2014-2027
Figure 6.4 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn),2014-2027
Figure 6.5 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), 2014-2027
Figure 6.6 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), 2014-2027
Figure 6.7 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), 2014-2027
Figure 6.8 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), 2014-2027
Figure 6.9 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), 2014-2027
Figure 7.1 Fusion Proteins as a Percentage of the Total Biologics Market: Revenue ($m), Market Share (%), 2016
Figure 7.2 Biosimilar Fusion Proteins Market Forecast: Revenue ($bn), 2014-2027
Figure 7.3 Biosimilar Etanercept Market Forecast: Revenue ($bn), 2014-2027
Figure 8.1 Diabetes Prevalence in Leading National Markets, 2012
Figure 8.2 Biosimilar Insulin Market Forecast: Revenue ($bn), 2014-2027
Figure 8.3 Biosimilar Insulin Submarket Forecasts: Revenues ($bn), 2014-2027
Figure 8.4 Drivers and Restraints for the Biosimilar Insulin Market, 2016
Figure 8.5 Biosimilar Human Insulin Submarket Revenue Forecast: Revenue ($bn), 2014-2027
Figure 8.6 Biosimilar Insulin Analogues Submarket Forecast: Revenue ($bn), 2014-2027
Figure 8.7 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($bn), 2014-2027
Figure 8.8 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($bn), 2014-2027
Figure 9.1 Biosimilar EPO Market Forecast: Revenue ($bn), 2014-2027
Figure 10.1 Biosimilar G-CSF Market Forecast: Revenue ($bn), 2014-2027
Figure 11.1 Biosimilar Interferons Market Forecast: Revenue ($bn), 2014-2027
Figure 11.2 Chronic Hepatitis B: Global Prevalence Share (%) by Region, 2014
Figure 11.3 Chronic Hepatitis C: Global Prevalence Share (%) by Region, 2014
Figure 11.4 Biosimilar Interferon Alfa Market Forecast: Revenue ($bn), 2014-2027
Figure 11.5 Biosimilar Interferon Beta Market Forecast: Revenue ($bn), 2014-2027
Figure 12.1 Biosimilar Growth Hormone Market Forecast: Revenue ($bn), 2014-2027
Figure 12.2 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), 2014-2027
Figure 13.1 Strengths and Weaknesses of the Biosimilars Market, 2016-2027
Figure 13.2 Opportunities and Threats for the Biosimilars Market, 2016-2027
Figure 13.3 Biosimilar Development Costs by Stage, 2016
Figure 13.4 Typical Biosimilar Development Timeline
Figure 14.1 Biosimilars and Follow-On Biologics Market: Revenue ($bn), by Sector, 2016, 2020 and 2027
Figure 14.2 Biosimilars and Follow-On Biologics Market: Revenue ($bn), by Region, 2016, 2020 and 2027

【レポートのキーワード】

バイオシミラー、バイオ後続品

★調査レポート[バイオシミラー及びバイオ後続品の世界市場] (コード:VGAIN705044)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイオシミラー及びバイオ後続品の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆